| Drug General Information |
| Drug ID |
D0S6TK
|
| Former ID |
DIB018041
|
| Drug Name |
tamatinib
|
| Synonyms |
R 406; R-406; R406 free base
|
| Drug Type |
Small molecular drug
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Clinical trial |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C22H23FN6O5
|
| InChI |
InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)
|
| InChIKey |
NHHQJBCNYHBUSI-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
16296087, 23397780, 42293201, 50077030, 57288231, 77344609, 99443630, 99460878, 103596121, 103904600, 103911497, 104103809, 104253192, 118049697, 121279875, 124772082, 126659679, 126726736, 135686088, 135686089, 135686106, 135686107, 135727442, 136367807, 136920409, 137275829, 141853025, 143498000, 152090530, 152234883, 152258324, 152344022, 160647163, 160968244, 162011591, 162202555, 162202679, 162920174, 164041983, 164824515, 170482429, 170483678, 170485720, 170496629, 170498439, 172912587, 174530755, 177748686, 178102333, 180190838
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase SYK |
Target Info |
Inhibitor |
[2]
|
|---|
| Proto-oncogene tyrosine-protein kinase receptor ret |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Osteoclast differentiation
|
|
Platelet activation
|
|
Natural killer cell mediated cytotoxicity
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
Tuberculosis
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesishsa04144:Endocytosis
|
|
Pathways in cancer
|
|
Thyroid cancer
|
|
Central carbon metabolism in cancer
|
|
PANTHER Pathway
|
B cell activation
|
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
|
BCR signaling pathway
|
|
GMCSF-mediated signaling events
|
|
Atypical NF-kappaB pathway
|
|
Osteopontin-mediated events
|
|
FAS (CD95) signaling pathway
|
|
Thromboxane A2 receptor signaling
|
|
IL2-mediated signaling events
|
|
Class I PI3K signaling events
|
|
Alpha-synuclein signalingret_pathway:Signaling events regulated by Ret tyrosine kinase
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
FCGR activation
|
|
Regulation of actin dynamics for phagocytic cup formation
|
|
Role of phospholipids in phagocytosis
|
|
DAP12 signaling
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Role of LAT2/NTAL/LAB on calcium mobilization
|
|
FCERI mediated MAPK activation
|
|
FCERI mediated Ca+2 mobilization
|
|
Integrin alphaIIb beta3 signaling
|
|
Interleukin-2 signaling
|
|
CLEC7A (Dectin-1) signaling
|
|
Dectin-2 family
|
|
Regulation of signaling by CBL
|
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
WikiPathways
|
IL-2 Signaling Pathway
|
|
IL-3 Signaling Pathway
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Signaling by the B Cell Receptor (BCR)
|
|
Interleukin-2 signaling
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
DAP12 interactions
|
|
B Cell Receptor Signaling Pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Integrin alphaIIb beta3 signaling
|
|
GPVI-mediated activation cascade
|
|
Regulation of toll-like receptor signaling pathway
|
|
IL-5 Signaling PathwayWP706:SIDS Susceptibility Pathways
|
|
Dopaminergic Neurogenesis
|
| References |
| REF 1 | Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol. 2009 Feb;85(2):130-6. |
|---|
| REF 2 | Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1944-9. |
|---|
